BG
WINT

BlackRock Group’s Windtree Therapeutics Inc WINT Stock Holding History

BlackRock Group’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,900
Closed -$87K – 2913
2014
Q1 		$87K Buy
+2,900
New +$97.6K ﹤0.01% 2585

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Group's WINT Position: Q2 2014 in Review

BlackRock Group sold out of Windtree Therapeutics Inc (WINT) in Q2 2014, closing a stake of 2,900 shares — an estimated $87K sold.

BlackRock Group first reported a position in WINT in Q1 2014 and held it in 1 quarter. The position peaked at $87K in Q1 2014. 67 funds tracked by Wall St. Rank hold WINT as of Q2 2014.

  • BlackRock Group reported no remaining Windtree Therapeutics Inc position as of Q2 2014 after selling out during the quarter.
  • BlackRock Group sold 2,900 Windtree Therapeutics Inc shares in Q2 2014, an estimated $87K.
  • BlackRock Group first reported a position in Windtree Therapeutics Inc in Q1 2014 and held it in 1 quarter.
  • BlackRock Group's Windtree Therapeutics Inc position peaked at $87K in Q1 2014.
  • 67 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q2 2014.

Based on BlackRock Group's 13F filing for Q2 2014, filed 6 Aug 2014.